DEFA14A: TransCode Acquires Polynoma, Boosts Immuno-Oncology Pipeline

TransCode Therapeutics, Inc. completes the acquisition of immuno-oncology firm ABCJ, LLC, adding a phase 3-ready melanoma vaccine to its pipeline, alongside a $25 million investment.

Summary

• TransCode Therapeutics, Inc. (RNAZ) acquired 100% of ABCJ, LLC, the parent company of Polynoma LLC, an immuno-oncology focused biopharmaceutical company, on October 8, 2025.
• The acquisition includes Polynoma's lead asset, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, which is described as 'phase 3-ready'.
• The total consideration for the acquisition of ABCJ's membership interests was $125,000, paid to DEFJ, LLC.
• TransCode issued 83,285 shares of common stock (9.99% of outstanding prior to closing) and 1,152.9568 shares of Series A Non-Voting Convertible Preferred Stock to DEFJ.
• The company also agreed to make up to $95.0 million in contingent milestone payments to DEFJ upon the achievement of certain milestones.
• Concurrently, TransCode entered into an Investment Agreement with DEFJ for $25.0 million, consisting of $20.0 million in cash and a $5.0 million promissory note due January 1, 2026, accruing 4% interest.
• This investment involved the issuance of 223.7337 shares of Series B Non-Voting Convertible Preferred Stock.
• Pro forma combined financial statements show a net loss of $(38,686) thousand for the nine months ended September 30, 2025, and $(41,184) thousand for the year ended December 31, 2024.
• Pro forma research and development expenses for the nine months ended September 30, 2025, were $23,272 thousand, and $24,363 thousand for the year ended December 31, 2024.
• As of September 30, 2025, the pro forma combined cash and cash equivalents were $19,822 thousand.
• The acquisition accounting includes a preliminary fair value of $165,173 thousand for acquired in-process research and development (IPR&D) assets and $36,173 thousand for goodwill.

Sentiment

Score: 3

Explanation: While the acquisition of a phase 3-ready asset in immuno-oncology offers long-term potential, the immediate financial burden, significant integration risks, potential for substantial shareholder dilution, and corporate governance concerns (controlled company status) create considerable uncertainty and downside risk. The company is still pre-revenue and faces substantial R&D costs.

Positives

• Acquisition of Polynoma, an immuno-oncology focused biopharmaceutical company, diversifies TransCode's business.
• Addition of seviprotimut-L, a 'phase 3-ready' novel polyvalent shed antigen vaccine for melanoma, to the pipeline.
• The vaccine is described as 'off-the-shelf' and allogenic, potentially offering broader applicability than personalized therapies.
• A $25.0 million investment from DEFJ, consisting of $20.0 million cash and a $5.0 million promissory note, provides funding for operations and R&D.
• TransCode has agreed to provide adequate funds for ABCJ/Polynoma to meet financial obligations for the next 12 months.

Negatives

• ABCJ/Polynoma has historically incurred significant losses and negative cash flows from operations, with an accumulated deficit of $210,715 thousand as of September 30, 2025.
• ABCJ/Polynoma has not generated any revenues to date from its product candidates.
• The combined entity is expected to incur substantial expenses related to the integration of Polynoma, which will likely result in significant charges against earnings.
• Accrued termination benefits of $2,397 thousand were recognized within ABCJ's accrued payroll and bonus as of September 30, 2025.
• The pro forma combined net loss is substantial, at $(38,686) thousand for the nine months ended September 30, 2025.

Risks

• No guarantee that the Acquisition will increase stockholder value or will not adversely affect the business.
• Significant integration challenges between TransCode's and Polynoma's businesses and employees could result in management and business disruptions.
• The Acquisition is subject to a contractual repurchase right by DEFJ in certain circumstances, which could materially adversely affect the price of common stock, results of operations, and financial condition.
• TransCode may be required to settle shares of Preferred Stock for cash if common stock is not delivered upon conversion or if the repurchase option is exercised, potentially leading to liquidity issues.
• Stockholders may experience substantial ownership dilution without receiving commensurate strategic and financial benefits from the Acquisition and Investment.
• Failure to successfully integrate the businesses of TransCode and Polynoma in the expected timeframe would adversely affect future results.
• Integration is a time-consuming and expensive process, potentially leading to loss of key employees, disruption of ongoing business, or inconsistencies in standards, controls, procedures, and policies.
• Delays encountered in the integration process could materially adversely affect expenses, operating results, financial condition, and the value of common stock.
• If DEFJ converts a substantial majority of its Preferred Stock, TransCode could become a 'controlled company' under Nasdaq listing standards, qualifying for exemptions from certain corporate governance requirements (e.g., majority independent directors, independent compensation committee).
• Concentration of voting power in DEFJ could delay, deter, or prevent a change of control or other business combination beneficial to stockholders, and may adversely affect the trading price of common stock.
• Failure to effectively manage expanded operations due to increased complexity could have a material adverse effect on business, financial condition, results of operations, and growth prospects.
• The accounting for the Acquisition may materially and adversely affect the amount of stockholders' equity, particularly if it is accounted for as an asset acquisition rather than a business combination.

Future Outlook

The proceeds from the $25.0 million investment are designated for funding operations and performing clinical and research & development activities. TransCode does not anticipate generating any revenues from Polynoma's product candidates until successful completion of required Phase 2 and 3 human clinical trials and obtaining regulatory approvals for commercialization.

Industry Context

This acquisition positions TransCode Therapeutics to expand its presence in the immuno-oncology sector, a rapidly evolving field in biopharmaceutical research. The addition of seviprotimut-L, a 'phase 3-ready' polyvalent shed antigen vaccine for melanoma, suggests a strategic move to acquire a late-stage asset with potential for broad application, distinguishing it from personalized vaccine approaches. The focus on R&D and clinical trials is typical for companies in this stage of biopharmaceutical development, where significant investment is required before potential revenue generation.

Corporate Governance

Related Party Transactions

• TransCode acquired ABCJ from DEFJ, LLC, which was a wholly owned subsidiary of CK Life Sciences Intl., (Holdings) Inc.
• Concurrently, TransCode entered into an Investment Agreement with DEFJ, LLC.
• DEFJ, LLC holds a significant amount of Preferred Stock and Common Stock in TransCode, potentially leading to a controlling interest.
• ABCJ's historical financials show amounts due to intermediate holding company, Conjoint Inc. ($4 thousand), and fellow subsidiaries, Fonjoint LLC ($2 thousand) and CK Life Sciences Limited ($8 thousand as of Sep 30, 2025).

Stakeholder Impact

• Shareholders: Potential for significant dilution of ownership interests due to the issuance of common and preferred stock, and if anticipated benefits are not fully realized. Risk of adverse impact on common stock trading price due to concentrated ownership.
• Employees: Integration challenges could lead to management and business disruptions, and potentially the loss of key employees.
• Creditors: The $5.0 million promissory note to DEFJ is due January 1, 2026, and is secured by Series B Preferred Stock. The potential need to cash settle Preferred Stock could impact liquidity.
• Customers/Patients: The acquisition of a phase 3-ready asset in immuno-oncology could eventually lead to new treatment options for melanoma patients, if successful.

Next Steps

• Finalize the acquisition accounting (including necessary valuation and other studies) within one year following completion of the Combination.
• Obtain stockholder approval for the conversion of the Series A and Series B Preferred Stock into common stock.
• Continue funding operations and performing clinical and research & development activities for Polynoma's product candidates.

Key Dates

Recommendation

The acquisition of a phase 3-ready asset in immuno-oncology offers long-term potential, but the immediate financial strain, integration risks, and significant dilution for existing shareholders create substantial near-term uncertainty. The potential for DEFJ to become a controlling shareholder and the associated corporate governance implications also warrant caution. Investors should hold to monitor integration progress, clinical trial outcomes, and the realization of anticipated synergies before making further investment decisions.

Keywords

TransCode Therapeutics, ABCJ LLC, Polynoma LLC, Acquisition, Immuno-oncology, Melanoma vaccine, Seviprotimut-L, Biopharmaceutical, SEC filing, RNAZ, Phase 3-ready, Investment Agreement, Corporate governance, Stockholder dilution